MaaT Pharma

Industry · 10 registered clinical trials — 1 currently recruiting.

Status	Trial	Phase	Started
Recruiting	Oral Pooled Fecal Microbiotherapy to Prevent Allogeneic Hematopoietic Cell Transplantation Complications (PHOE Transplant Complication	Phase 2	2023-10-31
Completed	Safety and Gut Microbiota Analysis of an Oral Microbiotherapy in Patients With Amyotrophic Lateral Sclerosis Amyotrophic Lateral Sclerosis, ALS	Phase 1	2023-06-08
Active Not Recruiting	MaaT013 As Salvage Therapy in Ruxolitinib Refractory GI-aGVHD Patients Acute Graft Versus Host Disease in Intestine, Steroid Refractory GVHD	Phase 3	2022-03-25
Unknown	Prospective Interventional Study Exploring the Microbiota Recolonization in SR-GvHD Patients Receiving MaaT013 Intestinal GVHD, Steroid Refractory GVHD	N/A	2021-10-06
Completed	Safety and Tolerability Evaluation of MaaT033 Hematologic Diseases, Chemotherapy Effect	Phase 1	2020-10-20
Completed	Treatment of Steroid Refractory Gastro-intestinal Acute GVHD afteR AllogeneiC HSCT With fEcal Microbiota tranS Fecal Microbiota Transplantation	Phase 2	2018-08-13
Terminated	Evaluation of Heterologous Fecal microbiotA Transfer in ICU Patients: a FeasibilitY and SafetY StudY Intensive Care Units, Fecal Microbiota Transplantation	Phase 2	2018-01-15
Completed	InterventiOnal Study of Bone and Joint Infections Related Gut dysbiosIS Bone and Joint Infection	N/A	2016-12-01
Completed	PreventiOn of DYSbioSis Complications With Autologous FMT in AML Patients Leukemia, Myeloid, Acute	Phase 1 / Phase 2	2016-06-01
Available	Early Access Program With MaaT013 in Steroid-refractory Acute Gastrointestinal Graft Versus Host Disease Acute Graft Versus Host Disease in Intestine, Steroid Refractory GVHD	—	—